Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Spark Therapeutics nets $172mm in initial public offering

Executive Summary

Gene therapy company Spark Therapeutics LLC netted $172mm in its initial public offering of 8.1mm shares (including the overallotment) for $23. Both the number of shares and price were upsized from planned terms: earlier this month Spark said it would sell 5.5mm shares for $15-17, and the company later amended that to 6.5mm shares at $19-21.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies